PMID: 6113579Jan 1, 1981Paper

Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings

Peptides
S ChiuR K Mishra

Abstract

The mechanism of action subserving the potential anti-Parkinsonian properties of L-prolyl-L-leucyl-glycinamide (PLG) was investigated in behavioural and neurochemical models of dopaminergic function in the rat. Acute administration of PLG (20 and 40 mg kg-1 SC) failed to alter appreciably the intensity of the cataleptic response elicited by haloperidol (3 mg kg-1 IP). By contrast, chronic PLG treatment (20, 40 and 80 mg kg-1 SC twice daily for five days) significantly attenuated haloperidol-induced catalepsy. The effect of PLG on in vitro dopamine/neuroleptic receptor binding in rat striatum as differentially labelled by apomorphine and spiroperidol was also examined. PLG selectively enhanced the affinity of the specific binding of agonist [3H] apomorphine to dopamine receptors in the striatum, but had no effect on [3H] spiroperidol binding. The behavioural and biochemical results obtained in the present study raise the possibility that PLG may facilitate nigro-striatal dopaminergic neurotransmission through interacting with a unique PLG receptor functionally coupled to the dopamine receptor-adenylate cyclase complex.

References

Nov 1, 1975·Pharmacology, Biochemistry, and Behavior·R M KostrzewaM A Spirtes
Jan 1, 1976·Pharmacology, Biochemistry, and Behavior·C W ChristensenM A Spirtes
Jun 10, 1977·Naunyn-Schmiedeberg's Archives of Pharmacology·S Björkman, H Sievertsson
May 1, 1978·The American Journal of Psychiatry·R H Ehrensing, A J Kastin
Jan 1, 1978·Annual Review of Biochemistry·A V SchallyC A Meyers
Sep 1, 1978·Pharmacology, Biochemistry, and Behavior·R M KostrzewaS K Sobrian
Jan 1, 1979·European Journal of Pharmacology·S Chiu, R K Mishra
Jan 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·R WalterL B Flexner
Apr 15, 1979·European Journal of Pharmacology·P Muller, P Seeman
Aug 1, 1979·European Journal of Pharmacology·H SchulzG Telegdy
Jun 18, 1971·Biochemical and Biophysical Research Communications·R M NairA V Schally
Nov 23, 1973·Science·E FriedmanS Gershon
May 1, 1974·Pharmacology, Biochemistry, and Behavior·N P Plotnikoff, A J Kastin

❮ Previous
Next ❯

Citations

Aug 1, 1989·Biulleten' eksperimental'noĭ biologii i meditsiny·N A Bondarenko, A V Val'dman
Feb 18, 1986·European Journal of Pharmacology·J R Martin, A E Takemori
Apr 12, 1989·European Journal of Pharmacology·R M KostrzewaA J Kastin
Nov 15, 1982·Life Sciences·R F RitzmannJ Z Fields
Oct 1, 1986·Pharmacology, Biochemistry, and Behavior·C Hara, A J Kastin
Jun 1, 1986·Pharmacology, Biochemistry, and Behavior·C Hara, A J Kastin
Jan 1, 1983·Neuroscience and Biobehavioral Reviews·T K von AlmenR D Olson
Jan 1, 1995·Neuroscience and Biobehavioral Reviews·R M Kostrzewa
Jan 1, 1982·Pharmacology & Therapeutics·D H Versteeg
Jan 1, 1983·Pharmacology & Therapeutics·R F RitzmannW Krivoy
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·S ChiuR K Mishra
Jan 1, 1993·Brain Research Bulletin·R M Kostrzewa, A J Kastin
Feb 25, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Justin PiazzaRam K Mishra
Nov 9, 2007·Peptides·Weihong Pan, Abba J Kastin
Mar 22, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Regina KatzenschlagerAndrew J Lees

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here